Randomized Phase II Trial Seeking the Most Promising Drug Association With Azacitidine- in Higher Risk Myelodysplastic Syndromes.
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2017
At a glance
- Drugs Azacitidine (Primary) ; Idarubicin; Lenalidomide; Valproic acid
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms AZA-PLUS
- Sponsors Assistance Publique Hopitaux de Paris
- 13 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 13 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jan 2018.
- 18 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.